| Vol. 5.36 – 19 October, 2020 |
| |
|
| | Researchers showed that hydrogen peroxide (H2O2), produced extracellularly, was necessary for the hypertrophic response of isolated cardiac myocytes and that aquaporin-1 facilitated the transmembrane transport of H2O2 through its water pore, resulting in activation of oxidant-sensitive kinases in cardiac myocytes. [Science Translational Medicine] |
|
|
| | PUBLICATIONSRanked by the impact factor of the journal |
| | | To test the hypothesis that the disruption caused by tetrachlorodibenzo-p-dioxin in the heart results from changes in DNA methylation and gene expression patterns of cardiomyocytes, scientists established a stable mouse embryonic stem cell line expressing a puromycin resistance selectable marker under control of the cardiomyocyte-specific Nkx2-5 promoter. [Toxicological Sciences] |
| | Both induced pluripotent stem cells derived from a Marfan syndrome (MFS)-patient and the line with the corrected fibrillin-1 mutation were differentiated to cardiomyocytes. Several functional analyses were performed on this model to study MFS related cardiomyopathy. [Scientific Reports] |
| | Scientists analyzed the applicability of a hydrojet-based method to deliver footprint-free induced pluripotent stem cell-derived cardiomyocytes into the myocardium. [Scientific Reports] |
| | Thre authors investigated the role of Type 2 inositol 1,4,5-trisphosphate receptor (IP3R2) in the differentiation of human embryonic stem cells (hESCs) to cardiomyocytes and in the hESC-derived cardiomyocytes. [Acta Pharmacologica Sinica] |
| | | Researchers showed that a PIX protein has an important function in muscle. From a genetic screen in C. elegans, they found that pix-1 was required for the assembly of integrin adhesion complexes at borders between muscle cells, and was required for locomotion of the animal. [Nature Communications] |
| | In a series of gain-of-function and loss-of-function experiments in rodent and human myotubes, scientists demonstrated that BNIP3L accumulation triggered mitochondrial depolarization, calcium-dependent activation of DNM1L/DRP1, and mitophagy. [Autophagy] |
| | Using immortalized patient-derived muscle cells and local intramuscular injections in the FLExDUX4 FSHD mouse model, investigators showed that their designed 2’-MOE gapmers significantly reduced DUX4 transcript levels in vitro and in vivo, respectively. [Molecular Therapy] |
| | Researchers investigated the role of mmu-miR-324-5p in the differentiation of C2C12 myoblasts and lipid droplet deposition in myotubes for future targeted therapies. [Molecular Therapy-Nucleic Acids] |
| | Scientists determined the physiological functions of Activin A, Notch and Sonic Hedgehog signaling in the proliferation of mouse C2C12 myoblasts and explored their interactions. [Molecular and Cellular Endocrinology] |
| |
|
| | All-trans retinoic acid (ATRA) could repress the PDGF-bb-induced excessive proliferation and migration of human umbilical vein smooth muscle cells, which was mediated by Rb-E2F dependent cell cycle inhibition. [Cardiovascular Drugs and Therapy] |
|
|
| | | The authors consider the biomolecular role for the vitamin D/Vitamin D receptor (VDR) axis in myogenesis, while also exploring global evidence for genomic and non‐genomic mechanisms of action for 1,25(OH)2D3/VDR. [Cell Biochemistry and Function] |
|
|
| | | Revance Therapeutics, Inc. announced positive topline results from its ASPEN-1 Phase III randomized, double-blind, placebo-controlled, parallel group clinical trial for its investigational drug candidate DaxibotulinumtoxinA for injection for the treatment of cervical dystonia, a chronic and debilitating neurologic condition affecting the muscles of the neck. [Revance Therapeutics, Inc.] |
|
|
| | The US FDA have granted a Rare Pediatric Disease designation to The Italfarmaco Group’s proprietary histone deacetylase inhibitor, Givinostat, for the treatment of Duchenne Muscular Dystrophy, which allows an expedited review process for new treatment modalities. The company also announced the completion of patient enrollment in the EPIDYS Phase III trial. [ITALFARMACO S.p.A.] |
|
|
| | | April 11 – April 13, 2021 San Diego, California, United States |
|
|
| | | | Center for Vascular and Inflammatory Diseases – Baltimore, Maryland, United States |
|
|
| | Sanford Research – Sioux Falls, South Dakota, United States |
|
|
| | Beth Israel Deaconess Medical Center – Boston, Massachusetts, United States |
|
|
| | University of Luxembourg – Luxembourg, Luxembourg |
|
|
| | University of Vermont – Burlington, Vermont, United States |
|
|
| |
|